Navigation Links
Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC
Date:6/3/2013

RIDGEFIELD, Conn., June 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced  results from the Phase III LUME-Lung 1 study showing that the addition of the investigational oncology compound nintedanib* to docetaxel improved progression-free survival (PFS) – the primary endpoint – as a second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) compared to docetaxel alone.1 Secondary endpoints included overall survival (OS).1 These results will be presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

"We are pleased to present the progression-free survival and overall survival data observed with the nintedanib/docetaxel combination in the LUME-Lung 1 clinical trial, in patients with advanced non-small cell lung cancer in the second-line treatment setting," said Berthold Greifenberg , MD, vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "These results were selected by ASCO for presentation at a late-breaking oral session at this year's annual meeting."

The trial enrolled 1,314 patients with advanced NSCLC whose disease progressed after first-line chemotherapy.1 Patients were randomly assigned to receive nintedanib plus docetaxel (n=655), a standard second-line chemotherapy, or docetaxel plus placebo (n=659).1

The primary endpoint was PFS as assessed by central independent review; results showed patients treated with nintedanib plus docetaxel lived for a median of 3.4 months before their tumor started to grow again, versus 2.7 months with docetaxel alone (HR 0.79; p=0.0019).1 

The secondary endpoint of OS was evaluated in the full study population, as well as in the sub-group of patients with adenocarcinoma histology &
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
4. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
5. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
6. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. Genetic clues to the causes of primary biliary cirrhosis
9. CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
10. BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)
11. Mayo Clinic and ReachMD Launch “Updates from Mayo Clinic” Featuring Expert Interviews and Panel Discussions on Mental Health in Pediatric Primary Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to ... ParticleView V19 with PVM technology , is now ... and measurement tool continuously captures high-resolution images under ... then automatically prepares a report pairing the most ... concentration changes. This compelling blend of high resolution ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... 2014 CanDiag, Inc., a University of ... changed its name to OncoTab, Inc. , “The ... we are today,” said CEO and Chief Science Officer, ... beyond breast cancer diagnostics to include imaging and therapies, ... evolution.” , Founded in 2011 by Dr. Mukherjee, an ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Mentice, Inc. and MATC have,forged a relationship ... on multiple,and mutually beneficial projects to further advance ... institutions throughout North America., Mentice,s Procedicus VIST ... attending physician to gain exposure to routine,and sophisticated ...
... Best-Selling Author to Devote Energies to Raising Awareness and Funds ... Cancers, Neurological, ... Other Serious Medical Conditions, CHARLOTTESVILLE, Va., Aug. 13 ... the development and,adoption of a breakthrough therapeutic technology -- Magnetic ...
... Inc.,(Nasdaq: ATSI ), manufacturer and marketer of ... participate at the Fourth,Annual Noble Financial Equity Conference ... Chief Financial Officer of ATS Medical, will,present at ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), Attendance ...
Cached Biology Technology:Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation 2John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technology's Potential to Help 'Millions of Patients' 2John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technology's Potential to Help 'Millions of Patients' 3ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference 2
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... today to the late Ernest Geskin, PhD, of Florham Park, ... professor at NJIT for more than 25 years. Sharing the ... and now a senior mechanical engineer for Marotta Controls, Montville. ... Forming of Tubular Parts" discloses a method for using propellant ...
... study finds that stroke patients, brains show strong cortical motor ... that offers new insight into stroke rehabilitation. Using functional ... monitored the brains of 24 individuals 12 who had ... as they watched others performing actions made using the arm ...
... 11, 2013 (BRONX, NY) Today, researchers at ... University convened a one-day conference on Jewish genetics designed ... Such research could help scientists identify causes and potential ... disorders afflicting the general population. The genetic ...
Cached Biology News:Patent awarded today to NJIT for novel use of water jets to create high tensile strength alloy parts 2Exercise for stroke patients' brains 2Albert Einstein College of Medicine hosts conference on Jewish genetic research 2
Request Info...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Request Info...
Biology Products: